; and (B) to serve as a scientific liaison between the review team and the applicant. (d) Reporting requirement Not later than one year after the date of the approval of an application under section 505(j) with respect to a drug for which the development and review is expedited under this section, the sponsor of such drug shall report to the Secretary on whether the drug has been marketed in interstate commerce since the date of such approval. . 4. Prohibition of payment under Medicare part B or coverage under Medicare part D for certain generic drugs manufactured outside of the United States (a) Medicare part B Section 1842(o) of the Social Security Act ( 42 U.S.C. 1395u(o) ) is amended by adding at the end the following new paragraph: (9) (A) Payment shall only be made under this part for a generic drug furnished on or after January 1, 2025, if it is a generic drug manufactured domestically (as described in section 2(b) of the Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act ). (B) Subparagraph (A) shall not apply, with respect to a drug, during any period for which the Secretary— (i) has notified the Administrator of the Centers for Medicare & Medicaid Services pursuant to section 2(a) of the Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act that the circumstances under paragraph (2), (3), or (4) of such section apply